Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 2 days agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 16, 1997 | Flutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-FLUTAMIDE (DIN 02230089) under ATC L02BB01 FLUTAMIDE. Indications are not published in the Drug Product Database… | DIN02230089 | withdrawnsource: Cancelled Post Marketsince Apr 30, 2018 | health-canada-dpd |
| Jan 15, 1997 | Interferon Alpha-2a | Health Canada CA | cancer not stated in this record | Marketed in Canada as ROFERON-A SOLUTION 18 MILLION I.U./3ML (DIN 02217066) under ATC L03AB04 INTERFERON ALFA-2A. Indications are not… | DIN02217066 | withdrawnsource: Cancelled Post Marketsince Jul 14, 2005 | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 31, 1996 | Flutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUTAMIDE (DIN 02059673) under ATC L02BB01 FLUTAMIDE. Indications are not published in the Drug Product Database —… | DIN02059673 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 18, 1996 | Raltitrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as TOMUDEX (DIN 02229566) under ATC L01BA03 RALTITREXED. Indications are not published in the Drug Product Database —… | DIN02229566 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 10, 1996 | Dacarbazine | Health Canada CA | cancer not stated in this record | Marketed in Canada as DTIC-DOME -PWS IV 200MG/VIAL (DIN 02154854) under ATC L01AX04 DACARBAZINE. Indications are not published in the Drug… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 23, 1996 | Cytarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYTARABINE INJECTION (DIN 02126656) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product… | DIN02126656 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 30, 1996 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as ARIMIDEX (DIN 02224135) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product Database —… | DIN02224135 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 30, 1996 | Diethylstilbestrol | Health Canada CA | cancer not stated in this record | Marketed in Canada as STILBESTROL TABLETS 0.1 MG (DIN 02091488) under ATC L02AA01 DIETHYLSTILBESTROL. Indications are not published in the… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 31, 1995 | Megestrol | Health Canada CA | cancer not stated in this record | Marketed in Canada as MEGESTROL (DIN 02195917) under ATC L02AB01 MEGESTROL. Indications are not published in the Drug Product Database —… | DIN02195917 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| withdrawnsource: Cancelled Post Marketsince Jul 31, 2014 |
| health-canada-dpd |
| Dec 31, 1996 | Doxorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as ADRIAMYCIN RDF (DIN 02065657) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product… | DIN02065657 | withdrawnsource: Cancelled Post Marketsince Aug 2, 2006 | health-canada-dpd |
| Dec 31, 1996 | Idarubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as IDAMYCIN - CAP 5MG (DIN 02166100) under ATC L01DB06 IDARUBICIN. Indications are not published in the Drug Product… | DIN02166100 | withdrawnsource: Cancelled Post Marketsince Aug 2, 2006 | health-canada-dpd |
| Dec 31, 1996 | Idarubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as IDAMYCIN - CAP 10MG (DIN 02166119) under ATC L01DB06 IDARUBICIN. Indications are not published in the Drug Product… | DIN02166119 | withdrawnsource: Cancelled Post Marketsince Aug 2, 2006 | health-canada-dpd |
| Dec 31, 1996 | Tamoxifen | Health Canada CA | cancer not stated in this record | Marketed in Canada as TAMONE - (10 MG) (DIN 02063778) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product… | DIN02063778 | withdrawnsource: Cancelled Post Marketsince Oct 2, 2007 | health-canada-dpd |
| Dec 31, 1996 | Tamoxifen | Health Canada CA | cancer not stated in this record | Marketed in Canada as TAMONE - (20 MG) (DIN 02063751) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product… | DIN02063751 | withdrawnsource: Cancelled Post Marketsince Oct 2, 2007 | health-canada-dpd |
| Dec 31, 1996 | Megestrol | Health Canada CA | cancer not stated in this record | Marketed in Canada as MEGESTROL (DIN 02185423) under ATC L02AB01 MEGESTROL. Indications are not published in the Drug Product Database —… | DIN02185423 | approved | health-canada-dpd |
| Dec 31, 1996 | Megestrol | Health Canada CA | cancer not stated in this record | Marketed in Canada as MEGESTROL (DIN 02185415) under ATC L02AB01 MEGESTROL. Indications are not published in the Drug Product Database —… | DIN02185415 | approved | health-canada-dpd |
| Dec 31, 1996 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CASODEX (DIN 02184478) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product Database —… | DIN02184478 | withdrawnsource: Cancelled Post Marketsince Mar 7, 2025 | health-canada-dpd |
| Dec 31, 1996 | Doxorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as ADRIAMYCIN RDF (DIN 02069563) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product… | DIN02069563 | withdrawnsource: Cancelled Post Marketsince Aug 2, 2006 | health-canada-dpd |
| Dec 30, 1996 | Idarubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as IDAMYCIN - CAP 25MG (DIN 02166127) under ATC L01DB06 IDARUBICIN. Indications are not published in the Drug Product… | DIN02166127 | withdrawnsource: Cancelled Post Marketsince Aug 2, 2006 | health-canada-dpd |
| Dec 30, 1996 | Buserelin | Health Canada CA | cancer not stated in this record | Marketed in Canada as SUPREFACT (DIN 02225166) under ATC L02AE01 BUSERELIN. Indications are not published in the Drug Product Database —… | DIN02225166 | approvedsource: Marketed | health-canada-dpd |
| Dec 2, 1996 | Mitoxantrone | Health Canada CA | cancer not stated in this record | Marketed in Canada as NOVANTRONE (DIN 02173468) under ATC L01DB07 MITOXANTRONE. Indications are not published in the Drug Product Database… | DIN02173468 | withdrawnsource: Cancelled Post Marketsince Aug 10, 2005 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Nov 15, 1996 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-METHOTREXATE (DIN 02170698) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product… | DIN02170698 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince May 31, 2005 |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Sep 5, 1996 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE SODIUM INJECTION USP (DIN 02161168) under ATC L01BA01 METHOTREXATE. Indications are not published in the… | DIN02161168 | withdrawnsource: Cancelled Post Marketsince Aug 2, 2006 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Aug 28, 1996 | Goserelin | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZOLADEX LA (DIN 02225905) under ATC L02AE03 GOSERELIN. Indications are not published in the Drug Product Database —… | DIN02225905 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Feb 23, 2009 |
| health-canada-dpd |
| Jul 30, 1996 | Diethylstilbestrol | Health Canada CA | cancer not stated in this record | Marketed in Canada as STILBESTROL TABLETS 1.0 MG (DIN 02091461) under ATC L02AA01 DIETHYLSTILBESTROL. Indications are not published in the… | DIN02091461 | withdrawnsource: Cancelled Post Marketsince Feb 23, 2009 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Dec 31, 1995 | Megestrol | Health Canada CA | cancer not stated in this record | Marketed in Canada as MEGESTROL (DIN 02195925) under ATC L02AB01 MEGESTROL. Indications are not published in the Drug Product Database —… | DIN02195925 | approvedsource: Marketed | health-canada-dpd |
| Dec 31, 1995 | Bacillus Calmette-Guerin (bcg) Strain Tice | Health Canada CA | cancer not stated in this record | Marketed in Canada as ONCOTICE (DIN 02153513) under ATC L03AX03 BCG VACCINE. Indications are not published in the Drug Product Database —… | DIN02153513 | approvedsource: Marketed | health-canada-dpd |
| Dec 31, 1995 | Vincristine | Health Canada CA | cancer not stated in this record | Marketed in Canada as VINCRISTINE SULFATE INJECTION (DIN 02143305) under ATC L01CA02 VINCRISTINE. Indications are not published in the Drug… | DIN02143305 | approvedsource: Marketed | health-canada-dpd |
| Dec 31, 1995 | Porfimer | Health Canada CA | cancer not stated in this record | Marketed in Canada as PHOTOFRIN (DIN 02020033) under ATC L01XD01 PORFIMER SODIUM. Indications are not published in the Drug Product… | DIN02020033 | withdrawnsource: Cancelled Post Marketsince Nov 21, 2014 | health-canada-dpd |
| Dec 31, 1995 | Porfimer | Health Canada CA | cancer not stated in this record | Marketed in Canada as PHOTOFRIN (DIN 02019876) under ATC L01XD01 PORFIMER SODIUM. Indications are not published in the Drug Product… | DIN02019876 | withdrawnsource: Cancelled Post Marketsince Jul 18, 2019 | health-canada-dpd |
| Dec 31, 1995 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE SODIUM INJECTION (DIN 02099705) under ATC L01BA01 METHOTREXATE. Indications are not published in the… | DIN02099705 | approvedsource: Marketed | health-canada-dpd |
| Dec 31, 1995 | Cytarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYTARABINE - PWS 2GM/VIAL (DIN 02167891) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug… | DIN02167891 | withdrawnsource: Cancelled Post Marketsince Oct 26, 2015 | health-canada-dpd |
| Dec 31, 1995 | Cytarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYTARABINE - PWS 1GN/VIAL (DIN 02167883) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug… | DIN02167883 | withdrawnsource: Cancelled Post Marketsince Oct 26, 2015 | health-canada-dpd |
| Dec 31, 1995 | Cytarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYTARABINE-PWS 100MG/VIAL (DIN 02167867) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug… | DIN02167867 | withdrawnsource: Cancelled Post Marketsince May 7, 2018 | health-canada-dpd |
| Dec 31, 1995 | Cytarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYTARABINE - PWS 500MG/VIAL (DIN 02167875) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug… | DIN02167875 | withdrawnsource: Cancelled Post Marketsince Oct 26, 2015 | health-canada-dpd |
| Dec 31, 1995 | Estramustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as EMCYT (DIN 02063794) under ATC L01XX11 ESTRAMUSTINE. Indications are not published in the Drug Product Database — see… | DIN02063794 | withdrawnsource: Cancelled Post Marketsince Apr 30, 2020 | health-canada-dpd |
| Dec 31, 1995 | Megestrol | Health Canada CA | cancer not stated in this record | Marketed in Canada as LINMEGESTROL - TAB 160MG (DIN 02176106) under ATC L02AB01 MEGESTROL. Indications are not published in the Drug… | DIN02176106 | withdrawnsource: Cancelled Post Marketsince May 29, 2006 | health-canada-dpd |
| Dec 31, 1995 | Megestrol | Health Canada CA | cancer not stated in this record | Marketed in Canada as LINMEGESTROL - TAB 40MG (DIN 02176092) under ATC L02AB01 MEGESTROL. Indications are not published in the Drug Product… | DIN02176092 | withdrawnsource: Cancelled Post Marketsince Aug 5, 2004 | health-canada-dpd |
| Dec 31, 1995 | Idarubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as IDAMYCIN POWDER -5MG/VIAL (DIN 02065630) under ATC L01DB06 IDARUBICIN. Indications are not published in the Drug… | DIN02065630 | withdrawnsource: Cancelled Post Marketsince Mar 21, 2014 | health-canada-dpd |
| Dec 31, 1995 | Idarubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as IDAMYCIN POWDER -10MG/VIAL (DIN 02068095) under ATC L01DB06 IDARUBICIN. Indications are not published in the Drug… | DIN02068095 | withdrawnsource: Cancelled Post Marketsince Mar 21, 2014 | health-canada-dpd |
| Dec 31, 1995 | Doxorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as ADRIAMYCIN RDF (DIN 02069555) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product… | DIN02069555 | withdrawnsource: Cancelled Post Marketsince Aug 2, 2006 | health-canada-dpd |
| Dec 31, 1995 | Epirubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as PHARMORUBICIN RDF (DIN 02069512) under ATC L01DB03 EPIRUBICIN. Indications are not published in the Drug Product… | DIN02069512 | withdrawnsource: Cancelled Post Marketsince Aug 2, 2006 | health-canada-dpd |
| Dec 31, 1995 | Interferon Beta-1b | Health Canada CA | cancer not stated in this record | Marketed in Canada as BETASERON (DIN 02169649) under ATC L03AB08 INTERFERON BETA-1B. Indications are not published in the Drug Product… | DIN02169649 | approvedsource: Marketed | health-canada-dpd |
| Dec 31, 1995 | Megestrol | Health Canada CA | cancer not stated in this record | Marketed in Canada as MEGACE OS (DIN 02168979) under ATC L02AB01 MEGESTROL. Indications are not published in the Drug Product Database —… | DIN02168979 | withdrawnsource: Cancelled Post Marketsince Oct 20, 2017 | health-canada-dpd |
| Dec 31, 1995 | Fluorouracil | Health Canada CA | cancer not stated in this record | Marketed in Canada as ADRUCIL (DIN 02063921) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug Product Database —… | DIN02063921 | withdrawnsource: Cancelled Post Marketsince Apr 8, 2004 | health-canada-dpd |
| Dec 31, 1995 | Docetaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as TAXOTERE (DIN 02177080) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see… | DIN02177080 | withdrawnsource: Cancelled Post Marketsince Jul 31, 2020 | health-canada-dpd |
| Dec 31, 1995 | Docetaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as TAXOTERE (DIN 02177099) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see… | DIN02177099 | withdrawnsource: Cancelled Post Marketsince Apr 30, 2018 | health-canada-dpd |
| Dec 31, 1995 | Epirubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as PHARMORUBICIN RDF (DIN 02065746) under ATC L01DB03 EPIRUBICIN. Indications are not published in the Drug Product… | DIN02065746 | withdrawnsource: Cancelled Post Marketsince Aug 2, 2006 | health-canada-dpd |
| Dec 31, 1995 | Melphalan | Health Canada CA | cancer not stated in this record | Marketed in Canada as ALKERAN (DIN 02087286) under ATC L01AA03 MELPHALAN. Indications are not published in the Drug Product Database — see… | DIN02087286 | approvedsource: Marketed | health-canada-dpd |
| Dec 31, 1995 | Doxorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOXORUBICIN HCL FOR INJ. U.S.P. 10MG/VIAL (DIN 02093057) under ATC L01DB01 DOXORUBICIN. Indications are not published… | DIN02093057 | withdrawnsource: Cancelled Post Marketsince Aug 13, 1998 | health-canada-dpd |